Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

What's new

Nafamostat to be evaluated as potential treatment for COVID-19

Daniel Anthony, Professor of Experimental Neuropathology in the Department of Pharmacology, is the scientific lead in a joint research team running a new clinical trial to evaluate the effectiveness for the treatment of COVID-19 of Nafamostat. This existing medicine, manufactured by Nichi-Iko Pharmaceutical Co Ltd, is a well-established treatment in Japan for pancreatitis. The company has generously donated supplies of Nafamostat for the initial clinical evaluation.

Oxford Pharmacology tops QS World Rankings once again in 2020

Oxford Department of Pharmacology has been judged best in the world for the second year in a row in the QS World Rankings, published today.

Pharmacology Workshop Manager, John Harris, receives Honorary Degree in recognition of his 50 years of service

John Harris, who started work in the Department of Pharmacology at the University of Oxford in 1969, was awarded an MA by the Vice-Chancellor Louise Richardson at a ceremony in the Sheldonian Theatre on Saturday 29 February 2020. John was described at the ceremony as "an essential pillar on whom to rely, to lean on in times of need, a craftsman of skill and imagination, a stalwart friend and steward to some of our most important scientific endeavours".

Upcoming talks and events